oral bisphosphonates (Fosamax, etc) might decrease the risk of breast cancer

Women are hearing that oral bisphosphonates (Fosamax, etc) might decrease the risk of breast cancer.

A new look at the Women's Health Initiative suggests one-third fewer breast cancers in postmenopausal women taking oral bisphosphonates.

Another observational study from Israel shows a similar benefit.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote